MTOR and hepatocellular carcinoma: mTOR inhibitors (Sirolimus and Everolimus) are being increasingly used specially in OLT for the treatment of HCC due to its antiproliferative effects [15, 21], but only after 1-month post-LT, given the potential deleterious effect of the drug on surgical wound healing and hepatic artery thrombosis [22].